Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Indexes end close to flat after hot inflation data ahead of Nvidia earnings
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Evolus (EOLS) Prices 5.217M Share Common Offering at $13/Sh
November 7, 2019 5:45 AM ESTEvolus, Inc. (NASDAQ: EOLS) (Evolus) announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions. Evolus is expected to receive net proceeds of approximately $63.5 million, after deducting underwriting... More
Evolus (EOLS) PT Raised to $14 at Barclays
November 5, 2019 4:46 AM ESTBarclays analyst Balaji Prasad raised the price target on Evolus (NASDAQ: EOLS) to $14.00 (from $13.00) while maintaining a Underweight rating.... More
Pre-Open Movers 11/04: (WMGI) (EOLS) (TWOU) Higher; (AVEO) (CHFS) (UAA) Lower (more...)
November 4, 2019 9:28 AM ESTToday's Pre-Open Movers
AVEO Oncology (NASDAQ: AVEO) 37.4% LOWER; provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 2019 overall survival (OS) analysis of the TIVO-3 trial and the Companys proposal to proceed with a New Drug Application (NDA) for tivozanib... In the FDAs preliminary feedback, based on its assessment of the totality of evidence presented to date, the FDA recommended that the Company not submit an NDA at this time. The FDA stated... More
Evolus (EOLS) Tops Q3 EPS by 15c, Revenues Beat
November 4, 2019 7:09 AM ESTEvolus (NASDAQ: EOLS) reported Q3 EPS of ($0.98), $0.15 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $4.05 million.
This was an exceptional quarter for the company on many fronts, in the U.S. and internationally,... More
AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales
November 1, 2019 7:52 AM EDTBy Tamara Mathias and Carl O'Donnell
(Reuters) - AbbVie Inc (NYSE: ABBV) on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc (NYSE: AGN).
Shares of the Illinois-based drugmaker rose more than 3% to $82.10.
AbbVie is counting on the Allergan acquisition, expected to close early next year, to help lessen its dependence on Humira, the world's top selling medicine, and diversify its product portfolio.
... More